BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of $0.16, $0.11 better than the analyst estimate of $0.05. Revenue for the quarter came in at $159.1 million versus the consensus estimate of $162.97 million.

GUIDANCE:

BioCryst Pharma sees FY2025 revenue of $590-600 million, versus the consensus of $626.1 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.